The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following new promising clinical trial data.
New data collected by the FDA has found that montelukast can bind to brain cells, which may explain the risk of mental health adverse effects linked to its use.